Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population. A post-hoc ...

A PSA of 127 indicated a high probability of prostate cancer, leading to immediate Lupron ADT therapy and radiation treatment ...

Multimodal treatment including radical prostatectomy might lead to improved survival in patients with oligometastatic prostate cancer treated with ADT. Men with oligometastatic prostate cancer (OmPCa) ...

SAN FRANCISCO -- Men with high-risk localized prostate cancer lived significantly longer with dose-escalated radiation therapy (RT) plus long-term androgen deprivation therapy (ADT), according to long ...

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond nine to 12 months of ADT.

ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC). This is an ASCO Meeting Abstract from the 2019 ...

First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors MEDLINE (1966-2018), Embase (1982-2018), ...

Results from the pivotal Phase III ARANOTE trial evaluating darolutamide plus androgen deprivation therapy (ADT) showed a statistically significant increase in radiological progression-free survival ...

Researchers at the Medical College of Georgia at Augusta University are searching for a better way to understand why many men with prostate cancer end up with Alzheimer’s disease, and whether it’s the ...